sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID‐19 Severity in Kidney Transplant Recipients
Immunity, Inflammation and Disease · 2025-10 · 13 (10)
DOI: 10.1002/iid3.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 27.10.2025. Verfasst von Yufei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: COVID-19, Kidney Transplantation, SARS-CoV-2, Fibrinogen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the National Natural Science Foundation of China (No. 82300857 to Bo Peng)..
Abstract (Originalsprache)
Background SARS‐CoV‐2 infection can induce persistent immunosuppression. Soluble fibrinogen‐like protein 2 (sFGL2) is an emerging immune regulator. However, the correlation between sFGL2 and SARS‐CoV‐2–induced immunosuppression in kidney transplant recipients (KTRs) remains unclear. Materials and Methods sFGL2 levels and peripheral blood lymphocyte subpopulations (PBLSs) were measured simultaneously in 50 KTRs with COVID‐19 on Day 1 and Day 7 after admission. An additional cohort of 15 stable KTRs without COVID‐19 was recruited as the control group. sFGL2 was quantified using enzyme‐linked immunosorbent assay, and PBLSs were analyzed with 6‐Color TBNK Reagent and quantified by flow cytometry. Results sFGL2 levels in the COVID‐19 group were significantly higher than those in the stable group [64.33 ng/mL, interquartile range (IQR) 45.32–111.94 ng/mL vs. 53.82 ng/mL, IQR 31.31–72.63 ng/mL; p = 0.029]. Within the COVID‐19 group, KTRs with pneumonia exhibited markedly higher sFGL2 levels than those without pneumonia (97.29 ng/mL, IQR 74.13–141.82 ng/mL vs. 45.13 ng/mL, IQR 33.07–55.82 ng/mL; p < 0.001). sFGL2 correlated with disease severity ( r = 0.692; p < 0.001), and sFGL2 > 70.58 ng/mL was identified as a risk factor for pneumonia [odds ratio (OR) 128.697; 95% confidence interval (CI) 8.339–1985.665; p < 0.001]. In addition, absolute PBLS counts were decreased in the COVID‐19 group, and CD3 + and CD8 + T‐cell counts were negatively correlated with sFGL2 ( r = –0.241 and –0.278; p = 0.032 and 0.013, respectively). With clinical improvement of COVID‐19, sFGL2 levels decreased while PBLS counts recovered. Conclusion sFGL2 was associated with immunosuppression, disease severity, and prognosis in KTRs with COVID‐19, suggesting that it could serve as a novel biomarker for monitoring immune status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha, China.
- NHC Key Laboratory of Translational Research on Transplantation Medicine, Changsha, China.
Förderung
- This study was supported by the National Natural Science Foundation of China (No. 82300857 to Bo Peng).
Zitieren
APA
Zhang, Y., Yang, M., Liu, K., Zhu, J., Wang, T., Ding, P., Ming, Y., & Peng, B. (2025). sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID‐19 Severity in Kidney Transplant Recipients. Immunity, Inflammation and Disease, 13(10). https://doi.org/10.1002/iid3.70296
Vancouver
Zhang Y, Yang M, Liu K, Zhu J, Wang T, Ding P, et al. sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID‐19 Severity in Kidney Transplant Recipients. Immunity, Inflammation and Disease. 2025;13(10). doi:10.1002/iid3.70296
BibTeX
@article{Zhang2025,
author = {Zhang, Yufei and Yang, Min and Liu, Kai and Zhu, Jiang and Wang, Tianyin and Ding, Peng and Ming, Yingzi and Peng, Bo},
title = {sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID‐19 Severity in Kidney Transplant Recipients},
journal = {Immunity, Inflammation and Disease},
year = {2025},
volume = {13},
number = {10},
doi = {10.1002/iid3.70296}
}
EUVIMED